Curasight - Providing answers for cancer patients

03 September 2020 - 09:11
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types, most notably for risk stratification in prostate cancer....
Spotlight (Sweden)
Curasight A/S
Curasight is active in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio includes, for example, research and development within Positron Emission Tomography (PET) and related ancillary services. The business is operating with the largest presence within Scandinavia. Curasight is headquartered in Copenhagen....
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date